A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Eur Urol

The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address:

Published: December 2018

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.eururo.2018.08.029	DOI Listing

Publication Analysis

joint statement

statement european

european association

association urology

urology renal

renal cell

cell cancer

cancer guidelines

guidelines panel

panel international

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!